当前位置:首页 >财报库 > 报告详情

晖致Viatris(VTRS)2025年第四季度及全年财报电话会议纪要「NASDAQ」(英文版)(51页).pdf

上传人: 1****1 编号:1155329 2026-03-12 51页 1.65MB

下载:

1、1This document contains proprietary information of Viatris Inc.Unauthorized use,duplication,dissemination or disclosure to third parties is strictly prohibited.2026 Viatris Inc.All Rights Reserved.VIATRIS and the Viatris Logo are trademarks of Mylan Inc.,a Viatris company.Q4&Full Year2025 EarningsFe

2、bruary 26,20262This document contains proprietary information of Viatris Inc.Unauthorized use,duplication,dissemination or disclosure to third parties is strictly prohibited.2026 Viatris Inc.All Rights Reserved.VIATRIS and the Viatris Logo are trademarks of Mylan Inc.,a Viatris company.Forward Looki

3、ng StatementsThis presentation contains“forward-looking statements”.These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.Such forward-looking statements may include,without limitation,statements about:2026 financial guidance;enterpr

4、ise-wide strategic review;building a more focused,efficient,and future-ready organization and positioning the company for sustained revenue and earnings growth beginning in 2026;opportunities to optimize our cost structure;improve our resource allocation;strengthen our operational efficiency;meaning

5、ful net cost savings;expect$650M in total cost savings by the end of 2028,with$400M net cost savings expected after reinvestment;expect global workforce reduction of up to 10%;enables reinvestment to enhance our growth profile through three strategic imperatives:drive our base business,fuel our inno

6、vative portfolio,modernize for sustainable growth;phasing of net savings expect to be 30%in 2026,30%in 2027 and 40%in 2028;our strategic imperatives;2026 strategic priorities,including deliver strong financial performance,drive commercial execution including launches,advance our pipeline including r

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **2025业绩表现**:总收入143亿美元(调整后EBITDA 41.6亿美元,调整后EPS 2.35美元),自由现金流19亿美元(剔除交易成本后22亿美元),同比增长2%(剔除Indore影响)。 2. **2026战略重点**:总收入预期增长3%( midpoint 147亿美元),调整后EBITDA 43亿美元,调整后EPS 2.40美元;计划实现净成本节省4亿美元(2026年占30%),全球裁员10%。 3. **研发进展**:2026年预计全球获批100+新产品,6款创新药候选者进入监管决策阶段,Phase 3试验读出启动。 4. **资本配置**:2026年超25亿美元现金可用于分配,包括股息(0.48美元/股)、股票回购及债务偿还(长期杠杆目标2.8x-3.2x)。 5. **风险提示**:包含前瞻性声明,实际结果可能受战略执行、监管、市场竞争等因素影响。
**成本 savings 计划?** **2026 增长动力?** **战略转型重点?**
客服
商务合作
小程序
服务号
折叠